ReviewInternational journal of molecular sciences2026
Layers of Hope: How Graphene and Nanostructures Hold Promise for Cancer Therapy.
Review in International journal of molecular sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
Cancer remains a challenge in modern medicine, characterized by high mortality rates and significant variability in treatment response. The urgent need for more effective and targeted therapies has driven the exploration of innovative strategies, including nanomedicine, which promises precise therapeutic delivery to tumor cells and minimal off-target effects in healthy tissues. This review critically summarizes recent advances in the use of nanomaterials for cancer therapy, focusing on graphene-based materials and dendrimers, whose complementary physicochemical architectures enable the rational design of hybrid nanoplatforms with enhanced therapeutic efficacy and biological performance. Due to their distinctive properties, such as high surface area, tunable architecture, and versatile surface functionalization, nanomaterials have emerged not only as drug delivery platform but also as active modulators of cancer-associated cellular processes. We discuss current evidence on nano-cell interactions, elucidating how these interactions can influence key cellular pathways relevant to tumor progression and treatment response. Despite their promise, a comprehensive understanding of the interactions between these nanomaterials and human cells is critical for clinical translation. A deeper mechanistic understanding of these interactions is essential to guide potential pathways for the development of effective therapeutics, paving the way for future advances in nanomedicine.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.